## **Humana** Healthy Horizons. in Louisiana

Notification:	HUM 7896
Category:	Drugs & Biologicals
Topic:	Louisiana Medicaid: infliximab and its biosimilars – HCPCS codes
	J1745, Q5103, Q5104, Q5109 and Q5121
What is changing? /	For providers with a specialty other than home infusion therapy or
Change Description:	pharmacy, we limit reimbursement of charges for HCPCS codes J1745,
	Q5103, Q5104, Q5109 or Q5121 to no more than 121 units per date of
	service for patients 15-17 years old who have any of the following
	diagnoses:
	<ul> <li>Mucocutaneous lymph node syndrome (Kawasaki disease)</li> </ul>
	• Multisystem inflammatory syndrome in children (MIS-C) post SARS-
	CoV-2 exposure
	• Ulcerative colitis (pediatric)
	<ul> <li>Acute graft-versus-host disease following hematopoietic cell</li> </ul>
	transplantation.
Why is Humana making this change?	The limitations above are established by the FDA-approved package
/ Change Reason:	insert and prescribing information and the pharmaceutical
	<u>compendia.</u>
	Note: The limitations described above are based on maximum
	dosages established in milligrams. If any units are denied, the
	provider may dispute the decision through the appropriate process.
	The provider may submit information, including medical notes
	showing the patient's body weight, that substantiates the medical
	necessity of the additional units.
Language:	<u>English</u>
Impacted Products:	Medicaid- Louisiana